Publications

2019

Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, et al. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nat Genet. 2019;51(9):1308-1314.
Orleans RA, Magro CM, Varghese GI. A subcutaneous nodule on the mid back. JAAD Case Rep. 2019;5(3):252-254.
Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJ. Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia. Br J Haematol. 2019;186(6):801.
Toyoda Y, Franck P, Brownstone ND, Lieberman M, Magro CM, Otterburn DM. Apocrine adenocarcinoma in the setting of apocrine hidrocystoma of the leg. Dermatol Online J. 2019;25(6).
Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, et al. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019;60(12):2917-2921.
Ware AD, Murdock T, Voltaggio L, Windon AL, Troncoso JC, Hruban RH, et al. The "Race" Toward Diversity, Inclusion, and Equity in Pathology: The Johns Hopkins Experience. Acad Pathol. 2019;6:2374289519873104.
Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, et al. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019;35(4):603-617.e8.
Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.
Goel R, Chopra S, Tobian AA, Ness PM, Frank SM, Cushing M, et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion. 2019;59(1):169-176.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700